Abstract 16153: The Association of Quality of Life and Race in Peripheral Arterial Disease Following Percutaneous Vascular Intervention: The Q-PAD Registry
Introduction: Black patients (pts) with peripheral arterial disease (PAD) are known to have higher prevalence, greater extent and severity, and worse outcomes compared to white pts with PAD. Yet, the association of race with quality of life (QOL) after peripheral vascular intervention (PVI) is less well known.
Methods: Peripheral Arterial Questionnaire (PAQ) is collected prospectively to evaluate QOL at baseline (pre-PVI) and at follow-up (1-6 month post-PVI). We conducted a retrospective review of this QOL data in 384 pts who had PVI in our center in 2012, in whom PAQ was available. We studied the differences in baseline and follow-up as well as the change in QOL between black (n=131, 34 %) and white pts (n=253, 66%).
Results: There were no significant differences between the QOL summary scores at baseline and follow-up between the 2 groups. Both groups improved similarly following PVI (p=0.09, figure 1). However compared with whites, blacks were on more cardiovascular medications including: Cilostazol (1.2% vs 18.2%: p<0.001), Nitrate (13.3% vs 25%: p=0.004) and Calcium Channel Blockers (CCB) (31.4% vs 47.7%: p=0.002). (Figure 2)
Conclusions: Despite the increased severity of PAD among black pts compared to white pts, QOL improved similarly in both groups after PVI. Black pts at discharge following PVI were receiving more vasodilator medications (Cilostazol, Nitrate and CCB) than whites. Data suggest that PVI should not be withheld in black pts, who demonstrate more severe PAD at baseline compared with white pts, as similar gains in QOL are attained in both racial groups with PVI.
Author Disclosures: A. Zaitoun: None. S. Al-Najafi: None. T. Musa: None. S. Szpunar: None. D. Light: None. H. Yamasaki: None. T. Lalonde: None. R.H. Mehta: None. H.S. Rosman: None.
- © 2016 by American Heart Association, Inc.